STAT3 and cancer: Hence, our findings elucidate a new mechanism underlying PD-L1 up-regulation, which is controlled by the activated p-STAT3/HLF/TFEB axis and provides a molecular basis for improving the clinical response rate and efficacy of targeted therapy and PD-1/PD-L1 blockade therapy in patients with cancer.